Valion Bio, Shear Kershman complete oral mucosal Entolimod formulation milestone
VBIO•Valion Bio reported successful formulation of oral mucosal Entolimod using Shear Kershman’s BioViscid platform. The next milestone is testing for measurable systemic exposure; management estimated a fully developed product could expand potential U.S. dose requirements by about 10 to 40 times.
1. Formulation milestone
Valion Bio reported successful formulation of oral mucosal Entolimod using Shear Kershman’s BioViscid drug-delivery platform. The program targets needle-free delivery, and the next milestone is testing whether dosing achieves measurable systemic exposure, with pharmacokinetics guiding dose and formulation optimization.
